Skip to main content
Open Access Publications from the University of California

Dermatology Online Journal

Dermatology Online Journal bannerUC Davis

Development of Sézary syndrome following the administration of dupilumab

  • Author(s): Tran, Jessica;
  • Morris, Lisa;
  • Vu, Alan;
  • Duvic, Madeleine
  • et al.

Dupilumab is a monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. It is the first biologic agent to demonstrate efficacy in treating moderate-to-severe refractory atopic dermatitis [1, 2]. Although dupilumab provides promise for the treatment of atopic and allergic conditions, clinicians should take into account its novelty and the potential for unexpected adverse events. We present a patient who developed Sézary syndrome following the initiation of dupilumab.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View